Recycled Blood Superior to Banked Blood for Surgery
|
By LabMedica International staff writers Posted on 25 May 2014 |
Patients whose own red blood cells (RBCs) are recycled during cardiopulmonary bypass (CPB) surgery fare better than those who get transfusions from a blood bank, according to a new study.
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Latest Hematology News
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








